


Vandetanib trifluoroacetate

Cat. No.:	HY-10260A
CAS No.:	338992-53-3
Molecular Formula:	C ₂₄ H ₂₅ BrF ₄ N ₄ O ₄
Molecular Weight:	589.38
Target:	VEGFR; Autophagy; Apoptosis
Pathway:	Protein Tyrosine Kinase/RTK; Autophagy; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC ₅₀ =40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC ₅₀ =110 nM) and EGFR/HER1 (IC ₅₀ =500 nM) ^[1] .		
IC₅₀ & Target	VEGFR2 40 nM (IC ₅₀)	VEGFR3 110 nM (IC ₅₀)	EGFR/HER1 500 nM (IC ₅₀)
In Vitro	Vandetanib inhibits VEGFR3 and EGFR with IC ₅₀ of 110 nM and 500 nM, respectively. Vandetanib is not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC ₅₀ of 1.1-3.6 μM, while almost has no activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC ₅₀ above 10 μM. Vandetanib inhibits VEGF-, EGF- and bFGF-stimulated HUVEC proliferation with IC ₅₀ of 60 nM, 170 nM and 800 nM, with no effect on basal endothelial cell growth. Vandetanib inhibits tumor cell growth with IC ₅₀ of 2.7 μM (A549) to 13.5 μM (Calu-6) ^[1] . Odanacatib is a weak inhibitor of antigen presentation, measured in a mouse B cell line (IC ₅₀ =1.5±0.4 μM), compared to the Cat S inhibitor LHVS (IC ₅₀ =0.001 μM) in the same assay. Odanacatib also shows weak inhibition of the processing of the MHC II invariant chain protein lip10 in mouse splenocytes compared to LHVS (minimum inhibitory concentration 1-10 μM versus 0.01 μM, respectively) ^[2] . Vandetanib suppresses phosphorylation of VEGFR-2 in HUVECs and EGFR in hepatoma cells and inhibits cell proliferation ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	Vandetanib (15 mg/kg, p.o.) has a superior anti-tumor effect than gefitinib in the H1650 xenograft model, and suppresses tumor growth with IC ₅₀ of 3.5±1.2 μM ^[3] . In tumor-bearing mice, vandetanib (50 or 75 mg/kg) suppresses phosphorylation of VEGFR-2 and EGFR in tumor tissues, significantly reduces tumor vessel density, enhances tumor cell apoptosis, suppresses tumor growth, improves survival, reduces number of intrahepatic metastases, and upregulates VEGF, TGF-α, and EGF in tumor tissues ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

PROTOCOL

Cell Assay ^[3]	Growth inhibition is measured by a modified MTT assay. Briefly, the cells are plated on 96-well plates at a density of 2000 cells per well and exposed to each gefitinib or vandetanib for 72 h. Each assay is performed in triplicate. The 50% inhibitory concentration (IC ₅₀) of each drug is determined as the mean±standard deviation (SD). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
----------------------------------	---

Animal Administration ^[3]

One million H1650 cells or H1650/PTEN cells (H1650 cells with a transfected PTEN gene) are injected subcutaneously into the backs of each mouse. On 10th day after injection, mice are randomly assigned to three groups, which receive either vehicle, vandetanib (15 mg/kg/day), or gefitinib (15 mg/kg/day). Vehicle, vandetanib, and gefitinib are administered once per day p.o., five times per week. Tumor volume (width×width×length/2) and body weight are determined periodically. Tumor volumes are expressed as mean±SD. Differences in tumor volume are evaluated using Student's t-test. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Nat Commun. 2020 Apr 20;11(1):1913.
- Oncogene. 2018 Mar;37(11):1417-1429.
- Cancer Lett. 2018 Jul 21;434:184-195.
- Carbohydr Polym. 2019 Mar 1;207:502-509.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. *Cancer Res.* 2002 Aug 15;62(16):4645-55.
- [2]. Hegedus C, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. *Biochem Pharmacol.* 2012 Aug 1;84(3):260-7.
- [3]. Takeda H, et al. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. *Exp Cell Res.* 2013 Feb 15;319(4):417-23.
- [4]. Inoue K, et al. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. *Clin Cancer Res.* 2012 Jul 15;18(14):3924-33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA